Chemistry:2-Aminoindane
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 2-indanylamine; 2-indanamine |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C9H11N |
| Molar mass | 133.194 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
2-Aminoindane (2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug.[1] It acts as a selective substrate for NET and DAT.[2][3]
Therapeutic and illicit uses
Synthetic aminoindanes were originally developed in the context of anti-Parkinsonian drugs as a metabolite of rasagiline and as a tool to be used in psychotherapy. Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters.[4] 2-AI is a rigid analogue of amphetamine and partially substitutes for it in rat discrimination tests.[5]
Chemical derivatives
There are a number of derivatives of 2-aminoindane and its positional isomer 1-aminoindane exist, including:
Legal status
China
As of October 2015 2-AI is a controlled substance in China.[6]
Sweden
Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.[7]
United States
2-Aminoindane is not scheduled at the federal level in the United States ,[8] but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
See also
- 2-Aminodilin (2-AD)
- 2-Aminotetralin (2-AT)
- Amphetamine
- Bath salts (drug)
References
- ↑ "The metabolic fate of two new psychoactive substances - 2-aminoindane and N-methyl-2-aminoindane - studied in vitro and in vivo to support drug testing". Drug Testing and Analysis 12 (1): 145–151. October 2019. doi:10.1002/dta.2699. PMID 31667988.
- ↑ "2-adrenergic receptors". Psychopharmacology 236 (3): 989–999. March 2019. doi:10.1007/s00213-019-05207-1. PMID 30904940.
- ↑ "Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives". Biochemical Pharmacology 88 (2): 237–44. March 2014. doi:10.1016/j.bcp.2014.01.024. PMID 24486525. http://edoc.unibas.ch/56166/1/20170921163100_59c3cd2473bad.pdf.
- ↑ "Synthetic Aminoindanes: A Summary of Existing Knowledge". Frontiers in Psychiatry 8: 236. 2017. doi:10.3389/fpsyt.2017.00236. PMID 29204127.
- ↑ "Structural variation and (+)-amphetamine-like discriminative stimulus properties". Pharmacology, Biochemistry, and Behavior 38 (3): 581–6. March 1991. doi:10.1016/0091-3057(91)90017-V. PMID 2068194.
- ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. http://www.sfda.gov.cn/WS01/CL0056/130753.html.
- ↑ "Åtta ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in sv). Folkhälsomyndigheten. 24 June 2019. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/juni/atta-amnen-foreslas-klassas-som-narkotika-eller-halsofarlig-vara/.
- ↑ "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.". http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm.
External links
 |  |
